You are here

Mouse Adult Stem Cells Developed into Heart and Blood Cells

Comment

Discuss

Key Step toward Clinical Testing of Stem Cells Developed from Patients' Skin Cells

DURHAM, N.C., April 30 - Researchers have succeeded in inducing stem cells grown from mouse skin cells to differentiate into functioning cardiovascular and blood cells, according to a study publishing online tomorrow in the journal "Stem Cells."

"Induced Pluripotent stem (iPS) cells are reprogrammed cells obtained by genetic manipulation of normal adult cells that then express capabilities similar to embryonic stem cells," explains Dr. Miodrag Stojković, Co-Editor of "Stem Cells." "That is, iPS cells are theoretically able to differentiate into 220 different cell types. For the first time, scientists from UCLA were able to induce the Differentiation of mouse iPS cells into functional heart cells, smooth muscle cells, and blood cells."

Katja Schenke-Layland and colleagues at UCLA performed a series of experiments using mouse iPS cells, using reprogrammed cells obtained from skin biopsies in adult mice. Although iPS cells are believed to be equivalent to embryonic stem cells, rigorous scientific studies are needed to confirm their potential to differentiate into specific types of cells.

Experiments in mice using iPS cells confirmed that the stem cells had differentiated into mature heart muscle cells (cardiomyocytes) and vascular smooth muscle cells (the specialized muscle cells lining the blood vessel walls). In addition, studies of cultured iPS cells showed markers characteristic of early cardiovascular and hematopoietic (blood-forming) cells. The iPS cells were essentially the same as mouse embryonic stem cells at the same stage of differentiation.

Using relatively simple laboratory techniques, the researchers were then able to induce iPS cells to develop into functional cardiomyocytes, smooth muscle cells, and hematopoietic cells. The functional cells showed only minor differences from cells developed from embryonic stem cells.

The ability to generate stem cells using the patient's own cells holds great promise for the treatment of currently incurable degenerative diseases, as well as for cell-based drug discovery. In recent months, reports from UCLA and other research groups have shown that human skin cells can be reprogrammed into cells that are nearly identical to Human Embryonic Stem Cells, without the nee

d to use human embryos or eggs.

The new results are an important milestone, extensively documenting the capability of inducing mouse iPS cells to develop into different types of functional cells. The next step will be to develop efficient, reliable, and safe techniques of generating human cardiovascular and hematopoietic cells for use in testing new "patient-tailored regenerative therapies," the researchers write.

Dr. Stojkovic adds, "The development of functional cells from iPS is a key step forward in the development of patient-specific embryonic stem cells for use in developing new treatments for conditions such as Alzheimer's disease, Parkinson's disease, and spinal cord injury, among others."

The article, entitled "Reprogrammed Mouse Fibroblasts Differentiate into Cells of the Cardiovascular and Hematopoietic Lineages," will be available online May 1, 2008, at: www.stemcells.com.

# # #
About AlphaMed Press
AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 26th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 13th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at http://www.alphamedpress.org.

CONTACTS (PLEASE DIRECT QUESTIONS RELATED TO CONTENT TO THE CORRESPONDING AUTHOR):

STEM CELLS' Editorial Office/Communications:
Corresponding Author:
George Kendall, GKendall@alphamedpress.com This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
W. Robb MacLellan, rmaclellan@mednet.ucla.edu This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Phone: 919-680-0011 (Ext. 224)

Cardiovascular Research Laboratory, University of California
STEM CELLS' Co-Editor:
Los Angeles School of Medicine
Professor Miodrag Stojkovic, mstojkovic@cipf.es This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Phone: 310-825-2556
Phone: +381 63 768 6185 © AlphaMed Press